Alto Neuroscience ANRO Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Direct external program expenses: by Product | ||||||
| ALTO-100 | $6.51M+10.9% | $5.87M+19.8% | $4.9M-13.6% | $5.67M-9.8% | $6.29M-14.7% | |
| ALTO-101 | $9.37M+88.1% | $4.98M+48.8% | $3.35M+1.0% | $3.31M-1.5% | $3.36M+20.1% | |
| ALTO-203 | $889K-45.1% | $1.62M-39.6% | $2.68M-23.8% | $3.52M-7.0% | $3.79M+3.2% | |
| ALTO-207 | $5.74M+259% | $1.6M+127% | $703K+96.4% | $358K— | $0— | |
| ALTO-300 | $5.05M+13.1% | $4.47M-5.6% | $4.73M-11.1% | $5.33M-14.3% | $6.22M-3.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alto Neuroscience break its business down?
- Alto Neuroscience (ANRO) reports direct external program expenses: by product across 5 parts — ALTO-100, ALTO-101, ALTO-203, ALTO-207 and ALTO-300. Each is extracted from the segment footnotes and tracked over time.
- Where does Alto Neuroscience's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alto Neuroscience's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.